Table II.

Inter-group comparisons of the levels of SBDPs at different time-points among groups (ng/ml).

Groups	Before treatment	1st day after treatment	3rd day after treatment	5th day after treatment	7th day after treatment
Control group	1.32±0.23	1.43±0.33	1.23±0.24	1.05±0.43	1.12±0.35
Group with mild symptoms	3.26±0.45	3.02±0.52	2.86±0.63	2.75±0.42	2.66±0.37
Group with moderate symptoms treated by regular therapy	4.68±0.68	4.56±0.67	4.42±0.59	4.27±0.54	4.03±0.53
Group with moderate symptoms treated by mild hypothermia therapy	4.69±0.95	3.58±0.92	3.17±0.78	2.96±0.64	2.74±0.62
Group with severe symptoms treated by regular therapy	6.85±1.23	6.23±1.15	6.10±1.05	5.89±0.98	5.76±0.93
Group with severe symptoms treated by mild hypothermia therapy	6.86±1.32	5.62±1.25	5.30±1.13	5.12±1.10	4.76±0.86

SBDPs, spectrin breakdown products.